Vicky Tsigkou, Gerasimos Siasos, Evangelos Oikonomou, Marina Zaromitidou, George Latsios, Manolis Vavuranakis, Spyridon Deftereos, Michael W. Cleman, Eleni Kokkou, Maria Limberi, Stathis Dimitropoulos, Thodoris Zografos, Smaragdi Marinaki, Christodoulos Stefanadis and Dimitris Tousoulis Pages 2773 - 2785 ( 13 )
Inflammation has been established as an important determinant of cardiovascular disease progression. Currently, clinical examination, laboratory and imaging tests are invaluable for the diagnosis, prognosis and disease monitoring. Novel inflammatory biomarkers are also used to better restratify patients in risk groups but their potential to guide treatment decisions and management of patients has not been extensively evaluated. Therefore, in this review article we present the most recent data concerning the use of inflammatory biomarkers in cardiovascular therapeutics.
Atherosclerosis, biomarkers, cardiovascular diseases, coronary artery disease, heart failure, hypertension, inflammation, peripheral artery disease, stroke.
, , , , , , , , , , , , , 1<sup>st</sup> Department of Cardiology, ‘Hippokration’ Hospital, University of Athens Medical School, Athens, Greece and Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA.